Expand NXL Menu
NXL MENU

NXL Latest Press Releases

-- June 16, 2026 --

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life Globe Newswire 9:15 AM

-- June 10, 2026 --

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. Globe Newswire 9:15 AM

-- June 4, 2026 --

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia Globe Newswire 10:00 AM

-- May 21, 2026 --

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury Globe Newswire 8:30 AM

-- May 19, 2026 --

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial Globe Newswire 8:30 AM

-- April 28, 2026 --

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia Globe Newswire 9:15 AM

-- April 22, 2026 --

Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment Globe Newswire 9:35 AM

-- April 15, 2026 --

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China Globe Newswire 10:00 AM

-- April 14, 2026 --

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 Globe Newswire 8:30 AM

-- April 9, 2026 --

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents Globe Newswire 7:47 AM

-- February 24, 2026 --

Nexalin Announces Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market Globe Newswire 8:07 AM

-- February 23, 2026 --

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders Globe Newswire 8:18 AM

-- February 5, 2026 --

Nexalin Launches NeuroCare, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care Globe Newswire 8:37 AM

-- February 2, 2026 --

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation Globe Newswire 8:45 AM

-- January 23, 2026 --

Nexalin Technology Receives Nasdaq Listing Status Notification Globe Newswire 5:15 PM
Market Data Delayed 15 Minutes